Day One Biopharmaceuticals(DAWN) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

DAWN Day One Biopharmaceuticals

Watchlist

8.020
-0.260-3.14%

Trading Mar 26 10:56 ET

812.86MMarket Cap-7.86P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Goldman Sachs Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $27
BenzingaMar 25 11:38 ET
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $30
Moomoo NewsMar 11 21:33 ET · Ratings
Day One Biopharmaceuticals | 10-K/A: Annual report (Amendment)
SECMar 6 17:02 ET · Announcements
$DAWN Stock Is up 8% Today. Here's What We See in Our Data.
Quiver QuantitativeMar 5 10:30 ET
Day One Biopharm Is Maintained at Overweight by JP Morgan
Dow JonesMar 5 10:08 ET · Ratings
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory
Yahoo FinanceMar 5 09:00 ET

Comments

ApexTradeZ

Dec 26, 2024 00:20

What’s the Top Undervalued BioTech

$Humacyte (HUMA.US)$ $uniQure NV (QURE.US)$ $Aquestive Therapeutics (AQST.US)$ $IDEAYA Biosciences (IDYA.US)$ $Day One Biopharmaceuticals (DAWN.US)$
share your thoughts & ideas explain why 2025 will be amazing several break free and run
apextradez Wins so can you

IDKWTFIMDOING

Jul 26, 2024 02:43

$Day One Biopharmaceuticals (DAWN.US)$
https://www.tipranks.com/news/blurbs/strong-buy-rating-for-day-one-biopharmaceuticals-amid-strategic-partnership-and-promising-financial-health?futusource=news_stock_stockpagenews&ns_stock_id=80620831336770&src=2&utm_medium=referral&utm_source=moomoo.com&client_hour_clock=24&clientlang=2

Trytosaveabit

Jul 25, 2024 15:47

$Day One Biopharmaceuticals (DAWN.US)$ Ipsen And Day One Enter Ex-U.S. Licensing Deal For Pediatric Brain Cancer Drug Tovorafenib
Benzinga· 01:54
Ipsen secures ex-U.S. regulatory and commercial rights to tovorafenib for most common childhood brain tumor, pediatric low-grade glioma (pLGG), and any future indications
OJEMDA (tovorafenib) is the first FDA-approved treatment for relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or V600 mutation, following the pivotal Phase II tria...

MARKET-TEST-DUMMY

Jun 20, 2024 04:39

turn around

$Day One Biopharmaceuticals (DAWN.US)$ we gonna see retraisement back to 18?

Trytosaveabit

Jun 12, 2024 19:34

Update

$XOMA Corp (XOMA.US)$ $Day One Biopharmaceuticals (DAWN.US)$ XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of Its Priority Review Voucher

DAWN Day One Biopharmaceuticals

Trade Overview

Capital Trend

News

Comments

Market Insights